4-(4-methyl-piperazino)-aniline; hydrochloride | 194799-59-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 4-(4-methyl-piperazino)-aniline; hydrochloride
• 英文别名: 4-(4-Methyl-piperazino)-anilin; Hydrochlorid；4-(4-methyl-1-piperazinyl)-benzenamine hydrochloride；4-(4-methyl-1-piperazinyl)benzenamine hydrochloride；4-(4-methylpiperazino)aniline hydrochloride；4-(4-Methylpiperazin-1-yl)aniline hydrochloride；4-(4-methylpiperazin-1-yl)aniline;hydrochloride
• CAS: 194799-59-2
• 化学式: C₁₁H₁₇N₃*ClH
• 分子量: 227.737
• InChiKey: NOUGUHFQRDXEFF-UHFFFAOYSA-N

物化性质

• 熔点：
  272-274 °C

计算性质

• 辛醇/水分配系数(LogP)：
  1.44
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  32.5
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-(4-methyl-piperazino)-aniline; hydrochloride 在 四(三苯基膦)钯 caesium carbonate 、 N,N-二异丙基乙胺 、 sodium iodide 作用下， 以 N-甲基吡咯烷酮 、 环丁砜 、 二甲基亚砜 为溶剂， 反应 0.41h， 生成 7-(4-chlorophenyl)-N-[4-(4-methylpiperazin-1-yl)phenyl]isoquinolin-1-amine
  参考文献：
  名称：

  [EN] QUINOLINE- AND ISOQUINOLINE-BASED COMPOUNDS EXHIBITING ATP-UTILIZING ENZYME INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF
  [FR] COMPOSES A BASE DE QUINOLEINE ET D'ISOQUINOLEINE PRESENTANT UNE ACTIVITE D'INHIBITION D'ENZYMES UTILISANT DE L'ATP ET COMPOSITIONS ET UTILISATIONS DE CEUX-CI

  摘要：

  揭示了基于喹啉和异喹啉的化合物展现出ATP利用酶抑制活性，以及使用展现出ATP利用酶抑制活性的化合物的方法和包含这些化合物的组合物。

  公开号：

  WO2005120509A1
• 作为产物：
  描述：

  1-甲基-4-(4-硝基苯基)哌嗪 在 钯 作用下， 以 甲醇 、 乙醇 为溶剂， 生成 4-(4-methyl-piperazino)-aniline; hydrochloride
  参考文献：
  名称：

  Novel N-[4-(aminosubstituted)phenyl]methanesulfonamides and their use as

  摘要：

  描述了新型N-[4-(氨基取代)苯基]甲磺酰胺类化合物及其作为心血管药物的用途，特别是作为抗心律失常药物的用途。还讨论了含有这类化合物的药物配方。

  公开号：

  US04906634A1

文献信息

• [EN] METHODS AND COMPOSITIONS OF NOVEL TRIAZINE COMPOUNDS<br/>[FR] METHODES ET COMPOSITIONS A BASE DE NOUVEAUX COMPOSES DE TRIAZINE
  申请人：REDDY US THERAPEUTICS INC

  公开号：WO2004026844A1

  公开（公告）日：2004-04-01

  The present invention relates to methods and compositions comprising compounds that treat pathophysiological conditions arising from inflammatory responses. In particular, the present invention is directed to compounds that inhibit or block glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells. The present invention relates to compounds that inhibit smooth muscle proliferation. In particular, the present invention is directed to compounds that inhibit smooth muscle cell proliferation by modulating HSPGs such as Perlecan. The present invention further relates to the use of compounds to treat vascular occlusive conditions characterized by smooth muscle proliferation such as restenosis and atherosclerosis.

  本发明涉及包含治疗由炎症反应引起的病理生理状况的化合物的方法和组合物。特别是，本发明涉及抑制或阻断在内皮细胞中由糖化蛋白产生的与信号传递相关的炎症反应的化合物。本发明还涉及抑制平滑肌细胞增殖的化合物。特别是，本发明涉及通过调节诸如Perlecan的HSPGs来抑制平滑肌细胞增殖的化合物。本发明进一步涉及使用化合物来治疗由平滑肌增殖特征的心血管闭塞性状况，如再狭窄和动脉粥样硬化。
• Triazine compounds and their analogs, compositions, and methods
  申请人：Timmer T. Richard

  公开号：US20050227983A1

  公开（公告）日：2005-10-13

  The present invention relates to triazine compounds and their analogs and derivatives, and methods and compositions comprising these compounds. The compounds and compositions of this invention are useful for, among other things, treating pathophysiological conditions arising from inflammatory responses, inhibiting or blocking glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells, inhibiting smooth muscle proliferation, treating vascular occlusive conditions characterized by smooth muscle proliferation such as restenosis and atherosclerosis, and the like.

  本发明涉及三嗪化合物及其类似物和衍生物，以及包含这些化合物的方法和组合物。本发明的化合物和组合物可用于治疗由炎症反应引起的病理生理条件，抑制或阻断糖化蛋白诱导内皮细胞中与信号相关的炎症反应，抑制平滑肌增殖，治疗以平滑肌增殖为特征的血管闭塞性疾病，如再狭窄和动脉粥样硬化等。
• Novel N-[4-(aminosubstituted)phenyl]methanesulfonamides and their use as
  申请人：Schering A.G.

  公开号：US04906634A1

  公开（公告）日：1990-03-06

  Novel N-[4-(aminosubstituted)phenyl]methanesulfonamides and their use as cardiovascular agents, especially as antiarrhythmic agents are described. Pharmaceutical formulations containing such compounds are also discussed.

  描述了新型N-[4-(氨基取代)苯基]甲磺酰胺类化合物及其作为心血管药物的用途，特别是作为抗心律失常药物的用途。还讨论了含有这类化合物的药物配方。
• 2,4-Di(hetero-)arylamino(-oxy)-5-substituted pyrimidines as antineoplastic agents
  申请人：——

  公开号：US20030181474A1

  公开（公告）日：2003-09-25

  Pyrimidine derivatives of formula (I) wherein Q 1 , Q 2 , G and R 1 are as defined within; and pharmaceutically acceptable salts and in vivo hydrolysable esters thereof are described. Processes for their manufacture, pharmaceutical compositions and their use as cyclin-dependent serine/threonine kinase (CDK) and focal adhesion kinase (FAK) inhibitors are also described. 1

  该式中的嘧啶衍生物（I），其中Q1、Q2、G和R1如定义；以及其药用盐和体内可水解酯已被描述。还描述了它们的制造过程、药用组合物以及作为细胞周期依赖性丝氨酸/苏氨酸激酶（CDK）和焦点粘附激酶（FAK）抑制剂的用途。
• 2,4,DI (hetero-) arylamino (-oxy) -5-substituted pyrimidines as antineoplastic agents
  申请人：Pease Janet Elizabeth

  公开号：US20050090515A1

  公开（公告）日：2005-04-28

  Pyrimidine derivatives of formula (I) wherein Q 1 , Q 2 , G and R 1 are as defined within; and pharmaceutically acceptable salts and in vivo hydrolysable esters thereof are described. Processes for their manufacture, pharmaceutical compositions and their use as cyclin-dependent serine/threonine kinase (CDK) and focal adhesion kinase (FAK) inhibitors are also described.

  本文描述了式(I)的嘧啶衍生物，其中Q1、Q2、G和R1如定义所述；以及其药学上可接受的盐和体内可水解的酯。还描述了它们的制造过程、制药组合物以及它们作为细胞周期依赖性丝氨酸/苏氨酸激酶(CDK)和焦点粘附激酶(FAK)抑制剂的用途。